Literature DB >> 9549431

[The chemical structure of new substance as the metabolite of baicalin and time profiles for the plasma concentration after oral administration of sho-saiko-to in human].

R Muto1, T Motozuka, M Nakano, Y Tatsumi, F Sakamoto, N Kosaka.   

Abstract

Baicalin (BG) is one of the major components of Sho-Saiko-To. We found a new substance as the metabolite of BG in human plasma after oral administration of Sho-Saiko-To. The metabolite was identified as baicalein 6-O-sulfate (BS) by comparing its retention time in HPLC and electrospray ionization mass spectra (ESI-MS)/MS methods with that of an authentic sample. Time profiles for the plasma concentrations of BS and BG after oral administration of Sho-Saiko-To (EK-9) at a daily dose (6 g), were investigated in 14 healthy male volunteers. The determination for the concentrations of BS and BG in human plasma was developed by the HPLC method using electrochemical detector (ECD). Each 1 ml of the plasma specimen was used for the solid phase extraction. The calibration curves of BS and BG showed a good linearity between 5 and 300 ng/ml. The quantitative limits of BS and BG in human plasma were 5 ng/ml. Using this method, BS was detected after 1 h, reached a maximum level at 5 h and then decreased to the level less than the quantitative limit after 36 h, and the plasma level of BS showed a slight peak at 24 h. BG was detected after 1 h, reached a maximum level at 5 h and then decreased to the level less than the quantitative limit after 36 h, and the plasma level of BG showed two peaks at 12 h and 24 h.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9549431     DOI: 10.1248/yakushi1947.118.3_79

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  8 in total

1.  Pharmacokinetics of scutellarin and its aglycone conjugated metabolites in rats.

Authors:  J M Huang; W Y Weng; X B Huang; Y H Ji; E Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

2.  Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines.

Authors:  S Chen; Q Ruan; E Bedner; A Deptala; X Wang; T C Hsieh; F Traganos; Z Darzynkiewicz
Journal:  Cell Prolif       Date:  2001-10       Impact factor: 6.831

3.  Iron-binding and anti-Fenton properties of baicalein and baicalin.

Authors:  Carlos A Perez; Yibin Wei; Maolin Guo
Journal:  J Inorg Biochem       Date:  2008-11-19       Impact factor: 4.155

Review 4.  Baicalein, Baicalin, and Wogonin: Protective Effects against Ischemia-Induced Neurodegeneration in the Brain and Retina.

Authors:  Li Pan; Kin-Sang Cho; Irvin Yi; Chi-Ho To; Dong Feng Chen; Chi-Wai Do
Journal:  Oxid Med Cell Longev       Date:  2021-06-29       Impact factor: 7.310

5.  Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal first-pass metabolism of flavonoid baicalein.

Authors:  Li Zhang; Ge Lin; Zhong Zuo
Journal:  Pharm Res       Date:  2006-11-16       Impact factor: 4.580

6.  Separation methods used for Scutellaria baicalensis active components.

Authors:  Hua-Bin Li; Yue Jiang; Feng Chen
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-12-05       Impact factor: 3.205

7.  Synthesis of Novel Baicalein Amino Acid Derivatives and Biological Evaluation as Neuroprotective Agents.

Authors:  Xiaohui Jia; Menglu Jia; Yuqin Yang; Di Wang; Fei Zhou; Wenxi Zhang; Xuemei Huang; Wenbo Guo; Desheng Cai; Hongshan Chen; Jinchai Qi; Shuqi Zhou; Haomiao Ren; Bing Xu; Tao Ma; Penglong Wang; Haimin Lei
Journal:  Molecules       Date:  2019-10-09       Impact factor: 4.411

8.  BA-j as a novel CDK1 inhibitor selectively induces apoptosis in cancer cells by regulating ROS.

Authors:  Shixuan Zhang; Yongming Bao; Xiulan Ju; Kangjian Li; Haiyan Shang; Lisha Ha; Yuan Qian; Liang Zou; Xiaodan Sun; Jing Li; Qianru Wang; Qingyu Fan
Journal:  Sci Rep       Date:  2015-09-02       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.